Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
2987- RES,    Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1
- in-vivo, Nor, NA
*VEGF↑, *iNOS↑, *NF-kB↑, *Sp1/3/4↑, *cardioP↑,
2988- RES,    The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation
- in-vitro, HCC, HUH7
TumCMig↓, TumCI↓, uPA↓, Sp1/3/4↓,
2991- RES,  Chemo,    Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells
- in-vitro, Melanoma, MSTO-211H - in-vitro, Nor, MeT5A
eff↑, selectivity↑, Sp1/3/4↓,
4570- RF,    Role of Mitochondria in the Oxidative Stress Induced by Electromagnetic Fields: Focus on Reproductive Systems
- Review, Nor, NA
*ETC↓, *ROS↑, *ROS∅,
4357- RF,    Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies
- Review, Var, NA
other↝, Dose↝, AntiTum↑, Ca+2↝, eff↝,
3729- RF,    Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer's Disease
- in-vivo, AD, NA
*cognitive↑, *Aβ↓, *ROS↓, *ATP↑,
3730- RF,    Transcranial electromagnetic treatment against Alzheimer's disease: why it has the potential to trump Alzheimer's disease drug development
- Review, AD, NA
*cognitive↑, *Aβ↓,
3731- RF,    Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice
- in-vivo, AD, NA
*cognitive↑, *Aβ↓, *neuroP↑, *memory↑,
3732- RF,    Electromagnetic treatment to old Alzheimer's mice reverses β-amyloid deposition, modifies cerebral blood flow, and provides selected cognitive benefit
- in-vivo, AD, NA
*cognitive↑, *Aβ↓,
3733- RF,    Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer's transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit?
- in-vivo, AD, NA
*Aβ↓, *cognitive↑, *mt-ROS↓, *ATP↑,
3736- RF,    Long-term electromagnetic pulse exposure induces Abeta deposition and cognitive dysfunction through oxidative stress and overexpression of APP and BACE1
- in-vivo, AD, NA
*cognitive↓, *BACE/β-secretase↑,
3738- RF,    Electromagnetic Field Stimulation Therapy for Alzheimer's Disease
- Review, AD, NA
*cognitive↑, *Aβ↓, *ROS↓, *memory↑, *Inflam∅,
3743- RF,    Repeated electromagnetic field stimulation lowers amyloid-β peptide levels in primary human mixed brain tissue cultures
- in-vitro, AD, NA
*Aβ↓, *toxicity∅, *APP∅,
3461- RF,    Electromagnetic Field Stimulation Therapy for Alzheimer’s Disease
- Review, AD, NA
*Aβ↓, *HSF1↑, *ROS↓, *Inflam↓, *cognitive↑, *memory↑, *eff↑,
3490- RF,    Multidimensional insights into the repeated electromagnetic field stimulation and biosystems interaction in aging and age-related diseases
- Review, AD, NA - Review, Park, NA
*OS↑, *memory↑, *cognitive↑, *memory↑, *Aβ↓, *eff↑, *HSF1↑, *HSP70/HSPA5↑,
6813- RF,    The effect of superposition of 900 MHz and incoherent noise electromagnetic fields on the induction of reactive oxygen species in SP2/0 cell line
- in-vitro, Melanoma, SP2/0
ROS↑,
6812- RF,    Frequency-Dependent Antioxidant Responses in HT-1080 Human Fibrosarcoma Cells Exposed to Weak Radio Frequency Fields
- in-vitro, Nor, HT1080
*SOD↑, *ROS⇅, *RPM↝,
6811- RF,    Continuous Exposure to 1.7 GHz LTE Electromagnetic Fields Increases Intracellular Reactive Oxygen Species to Decrease Human Cell Proliferation and Induce Senescence
- in-vitro, Liver, HUH7 - in-vitro, Liver, Hep3B - in-vitro, Cerv, HeLa - in-vitro, neuroblastoma, SH-SY5Y - in-vitro, Nor, IMR90
TumCP↓, eff↑, ROS↑, eff↓,
6810- RF,    SUMMARY OF SAFETY AND PROBABLE BENEFIT (SSPB)
- Trial, HCC, NA
Dose↝, Dose↝, Dose↝, OS↑,
6809- RF,    Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields
- in-vitro, GBM, U251
TumCP↓, Dose↝, eff↑, other↝, Dose↝, Dose↝, other↝, VGCC↑, Ca+2↑,
6808- RF,    Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma
- Trial, HCC, NA
OS↑, *toxicity↓, Dose↝, TumCG↓, Dose↝, Dose↝, Dose↝, eff↑,
6807- RF,    Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 T-type voltage-gated calcium channels and Ca2+ influx
- NA, HCC, NA
TumVol↓, Ca+2↑, TumCG↓, Dose↝,
6935- RF,    Effects of pulsed electromagnetic fields on benign prostate hyperplasia
- Human, BPH, NA
*Dose↝, *PV↓, *UFR↑, *UR↓, *QoL↑, *Dose↝, *Dose↝, *Dose↝, *Dose↝,
7149- Rhe,    Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cells
- in-vitro, PC, NA
TumCCA↑, Casp↑, mt-Apoptosis↑, PI3K↓, Akt↓, ChemoSen↑, ROS↑, eff↓,
3015- RosA,  Rad,    Rosmarinic Acid Prevents Radiation-Induced Pulmonary Fibrosis Through Attenuation of ROS/MYPT1/TGFβ1 Signaling Via miR-19b-3p
- in-vivo, Nor, IMR90
*radioP↑, *Inflam↓, *ROS↓, *NF-kB↓, *Rho↓, *ROCK1↓, *other↓,
3016- RosA,    Rosmarinic Acid Inhibits Cell Growth and Migration in Head and Neck Squamous Cell Carcinoma Cell Lines by Attenuating Epidermal Growth Factor Receptor Signaling
- in-vitro, HNSCC, UM-SCC-6 - in-vitro, HNSCC, UM-SCC-10B
chemoP↓, EGF↓, tumCV↓, TumCMig↓, ROS↓, PI3K↓, Akt↓, ERK↓, antiOx↑, p‑EGFR↓,
3017- RosA,  Per,    Molecular Mechanism of Antioxidant and Anti-Inflammatory Effects of Omega-3 Fatty Acids in Perilla Seed Oil and Rosmarinic Acid Rich Fraction Extracted from Perilla Seed Meal on TNF-α Induced A549 Lung Adenocarcinoma Cells
- in-vitro, Lung, A549
TumCD∅, ROS↓, IL1β↓, IL6↓, IL8↓, TNF-α↓, COX2/PTGS2↓, SOD2↓, FOXO1↓, NF-kB↓, JNK↓, antiOx↑, tumCV∅,
3018- RosA,    Rosemary (Rosmarinus officinalis L.) polyphenols and inflammatory bowel diseases: Major phytochemicals, functional properties, and health effects
- Review, IBD, NA
*Inflam↓, *GutMicro↑, *antiOx↑, *NF-kB↓, *NLRP3↓, *STAT3↓, *NRF2↑,
3019- RosA,    Orally administered rosmarinic acid is present as the conjugated and/or methylated forms in plasma, and is degraded and metabolized to conjugated forms of caffeic acid, ferulic acid and m-coumaric acid
- in-vivo, Nor, NA
*BioAv↝, *Half-Life↝, *Half-Life↑, *Half-Life↝, *BioAv↑,
3020- RosA,    Protective Effect of Rosmarinic Acid on Endotoxin-Induced Neuronal Damage Through Modulating GRP78/PERK/MANF Pathway
- in-vivo, Nor, NA - in-vitro, NA, SH-SY5Y
*cognitive↑, *PERK↓, *GRP78/BiP↓, *ER Stress↓,
3021- RosA,    Rosmarinic acid ameliorates septic-associated mortality and lung injury in mice via GRP78/IRE1α/JNK pathway
- in-vivo, Sepsis, NA
*eff↑, *SOD↑, *MDA↓, *GRP78/BiP↓, *IRE1↓, *JNK↓, *Sepsis↓,
3022- RosA,    Rosmarinic acid against cognitive impairment via RACK1/HIF-1α regulated microglial polarization in sepsis-surviving mice
- in-vitro, Sepsis, NA
*cognitive↑, *neuroP↑, *GlucoseCon↑, *Hif1a↓,
3023- RosA,    Rosmarinic acid alleviates septic acute respiratory distress syndrome in mice by suppressing the bronchial epithelial RAS-mediated ferroptosis
- in-vivo, Sepsis, NA
*GPx4↑, *Inflam↓, *ER Stress↓, *Ferroptosis↓, *Sepsis↓, *GRP78/BiP↓, *IRE1↓, JNK↓,
3024- RosA,    rmMANF prevents sepsis-associated lung injury via inhibiting endoplasmic reticulum stress-induced ferroptosis in mice
- in-vivo, Sepsis, NA
*Ferroptosis↓, *GRP78/BiP↓, *PERK↓, *ATF4↓, *Sepsis↓, *GSH↑, *SOD↑, *Catalase↑,
3025- RosA,    Rosmarinic acid alleviates intestinal inflammatory damage and inhibits endoplasmic reticulum stress and smooth muscle contraction abnormalities in intestinal tissues by regulating gut microbiota
- in-vivo, IBD, NA
*GutMicro↑, *ROCK1↓, *Rho↓, *CaMKII ↓, *Zeb1↓, *ZO-1↓, *E-cadherin↓, *IL1β↓, *IL6↓, *TNF-α↓, *GRP78/BiP↓, *PERK↓, *IRE1↓, *ATF6↓, *CHOP/DDIT3↓, *Casp12↓, *Casp9↓, *BAX↓, *Casp3↓, *Cyt‑c↓, *RIP1↓, *MLKL↓, *IL10↑, *Bcl-2↑, *ER Stress↓,
3026- RosA,    Modulatory Effect of Rosmarinic Acid on H2O2-Induced Adaptive Glycolytic Response in Dermal Fibroblasts
- in-vitro, Nor, NA
*ROS↓, *ATP↑, *NADPH↓, *HK2↓, *PFK2↓, *LDHA↓, *GSR↑, *GPx↑, *Prx↑, *Trx↑, *antiOx↑, *GSH↑, *ROS↓, *GlucoseCon↓, *lactateProd↓, *Glycolysis↝, *ATP↑, *NADPH↓, *PPP↓,
3027- RosA,    Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway
- in-vitro, HCC, SMMC-7721 cell
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, TumCMig↓, MMPs↓, Vim↓,
3014- RosA,    Rosmarinic Acid Supplementation Acts as an Effective Antioxidant for Restoring the Antioxidation/Oxidation Balance in Wistar Rats with Cadmium-Induced Toxicity
- in-vivo, Nor, NA
*antiOx↑, *Thiols↑, *GSH↑, *TAC↑, *SOD↑, *GPx↑, *Catalase↑, *ALP↓, *ALAT↓, *AST↓, *creat↓, *BUN↓, *H2O2↓, *MDA↓, *ROS↓, cardioP↑, hepatoP↑, neuroP↑,
3013- RosA,    Rosmarinic acid inhibits angiogenesis and its mechanism of action in vitro
- in-vitro, NA, NA
*BioAv↑, *antiOx↑, *Inflam↓, *ROS↓, *VEGF↓, *IL8↓,
3012- RosA,  Rad,    Rosmarinic Acid Prevents Radiation-Induced Pulmonary Fibrosis Through Attenuation of ROSMYPT1TGFβ1 Signaling Via miR-19b-3p
- in-vitro, Nor, IMR90
*Inflam↓, *ROS↓, *p‑NF-kB↓, *Rho↓, *ROCK1↓, *radioP↑, *MCP1/CCL2↓, *RANTES↓, *ICAM-1↓, *PGC1A↑, *NOX4↓, *Dose↝,
3011- RosA,    Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition
- in-vitro, GBM, SH-SY5Y - in-vitro, Lung, A549 - in-vitro, Nor, HEK293 - in-vitro, Nor, MCF10
MARK4↓, p‑tau↓, selectivity↑, *toxicity∅,
3010- RosA,    Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation
- in-vitro, Lung, A549 - in-vivo, NA, NA
TumCG↓, Ki-67↓, FABP4↑, PPARα↑, ROS↑, Apoptosis↑, MMP9↓, IGFBP3↓, MMP2↓, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, Gli1↓, PPARγ↑, Cyt‑c↑,
3009- RosA,    Rosmarinic acid sensitizes cell death through suppression of TNF-alpha-induced NF-kappaB activation and ROS generation in human leukemia U937 cells
- in-vitro, AML, U937
TNF-α↓, NF-kB↓, ROS↓, IAP1↓, IAP2/BIRC3↓, XIAP↓,
3008- RosA,    Rosmarinic acid decreases viability, inhibits migration and modulates expression of apoptosis-related CASP8/CASP3/NLRP3 genes in human metastatic melanoma cells
- in-vitro, Melanoma, SK-MEL-28
tumCV↓, TumCMig↓, ROS↓, Casp3↑, selectivity↑, Casp8↑, NLRP3↓,
3007- RosA,    Hepatoprotective effects of rosmarinic acid: Insight into its mechanisms of action
- Review, NA, NA
*ROS↓, *lipid-P↓, *Inflam↓, *neuroP↑, *angioG↓, *eff↑, *AST↓, *ALAT↓, *GSSG↓, *eNOS↓, *iNOS↓, *NO↓, *NF-kB↓, *MMP2↓, *MDA↓, *TNF-α↓, *GSH↑, *SOD↑, *IL6↓, *PGE2↓, *COX2/PTGS2↓, *mTOR↑,
3006- RosA,    Rosmarinic acid attenuates glioblastoma cells and spheroids’ growth and EMT/stem-like state by PTEN/PI3K/AKT downregulation and ERK-induced apoptosis
- in-vitro, GBM, U87MG - in-vitro, GBM, LN229
TumCG↓, EMT↓, SIRT1↓, FOXO1↓, NF-kB↓, angioG↓, ROS↓, PTEN↓, PI3K↓, Akt↓, *Inflam↓, *cardioP↑, *hepatoP↑, *neuroP↑, Warburg↓,
3005- RosA,    Nanoformulated rosemary extract impact on oral cancer: in vitro study
- in-vitro, Laryn, HEp2
TumCCA↑, ROS↑, Bcl-2↓, BAX↑, Casp3↑, P53↑, necrosis↑, eff↑, BioAv↑,
3004- RosA,    Rosmarinic acid counteracts activation of hepatic stellate cells via inhibiting the ROS-dependent MMP-2 activity: Involvement of Nrf2 antioxidant system
- in-vitro, Nor, HSC-T6
*GSH↑, *MMP2↓, *ROS↓, *lipid-P↓, *NRF2↑,
3003- RosA,    Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases
- Review, Var, NA - Review, AD, NA - Review, Park, NA
*Inflam↓, *antiOx↑, *neuroP↑, *IL6↓, *IL1β↓, *NF-kB↓, *PGE2↓, *COX2/PTGS2↓, *MMP↑, *memory↑, *ROS↓, *Aβ↓, *HMGB1↓, TumCG↓, MARK4↓, Zeb1↓, MDM2↓, BNIP3↑, ASC↑, NLRP3↓, PI3K↓, Akt↓, Casp1↓, E-cadherin↑, STAT3↓, TLR4↓, MMP↓, ICAM-1↓, AMPK↓, IL6↑, MMP2↓, Warburg↓, Bcl-xL↓, Bcl-2↓, TumCCA↑, EMT↓, TumMeta↓, mTOR↓, HSP27↓, Casp3↑, GlucoseCon↓, lactateProd↓, VEGF↓, p‑p65↓, GIT1↓, FOXM1↓, cycD1/CCND1↓, CDK4↓, MMP9↓, HDAC2↓,
3002- RosA,    Anticancer Effects of Rosemary (Rosmarinus officinalis L.) Extract and Rosemary Extract Polyphenols
- Review, Var, NA
TumCG↓, TumCP↓, TumCCA↑, ChemoSen↑, NRF2↑, PERK↑, SESN2↑, HO-1↑, cl‑Casp3↑, ROS↑, UPR↑, ER Stress↑, CHOP/DDIT3↑, HER2/EBBR2↓, ER-α36↓, PSA↓, BAX↑, AR↓, P-gp/ABCB1↓, Cyt‑c↑, HSP70/HSPA5↑, eff↑, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, cl‑PARP↑, eff↑,

Showing Research Papers: 6951 to 7000 of 8269
Prev Page 140 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   HO-1↑, 1,   NRF2↑, 1,   ROS↓, 5,   ROS↑, 6,   SOD2↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

EGF↓, 1,   MMP↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↓, 1,   FABP4↑, 1,   GlucoseCon↓, 1,   lactateProd↓, 1,   PPARα↑, 1,   PPARγ↑, 1,   SIRT1↓, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 6,   p‑Akt↓, 1,   Apoptosis↑, 2,   mt-Apoptosis↑, 1,   BAX↑, 2,   Bcl-2↓, 2,   Bcl-xL↓, 1,   Casp↑, 1,   Casp1↓, 1,   Casp3↑, 3,   cl‑Casp3↑, 1,   Casp8↑, 1,   Cyt‑c↑, 2,   IAP1↓, 1,   IAP2/BIRC3↓, 1,   JNK↓, 2,   MDM2↓, 1,   necrosis↑, 1,   TumCD∅, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,   Sp1/3/4↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 3,   tumCV↓, 2,   tumCV∅, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   ER Stress↑, 1,   HSP27↓, 1,   HSP70/HSPA5↑, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

BNIP3↑, 1,   SESN2↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 4,   ERK↓, 1,   FOXM1↓, 1,   FOXO1↓, 2,   Gli1↓, 1,   HDAC2↓, 1,   IGFBP3↓, 1,   mTOR↓, 3,   p‑mTOR↓, 1,   p‑P70S6K↓, 1,   PI3K↓, 6,   PTEN↓, 1,   STAT3↓, 1,   TumCG↓, 6,   VGCC↑, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 2,   Ca+2↝, 1,   E-cadherin↑, 1,   ER-α36↓, 1,   GIT1↓, 1,   Ki-67↓, 1,   MARK4↓, 2,   MMP2↓, 2,   MMP9↓, 2,   MMPs↓, 1,   TumCI↓, 3,   TumCMig↓, 4,   TumCP↓, 4,   TumMeta↓, 1,   uPA↓, 1,   Vim↓, 1,   Zeb1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   p‑EGFR↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↑, 1,   COX2/PTGS2↓, 1,   ICAM-1↓, 1,   IL1β↓, 1,   IL6↓, 1,   IL6↑, 1,   IL8↓, 1,   NF-kB↓, 3,   p‑p65↓, 1,   PSA↓, 1,   TLR4↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

p‑tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 2,   Dose↝, 12,   eff↓, 2,   eff↑, 7,   eff↝, 1,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   p‑EGFR↓, 1,   FOXM1↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 1,   IL6↑, 1,   Ki-67↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   cardioP↑, 1,   chemoP↓, 1,   hepatoP↑, 1,   neuroP↑, 1,   OS↑, 2,   TumVol↓, 1,  
Total Targets: 127

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

PV↓, 1,   UFR↑, 1,   UR↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 5,   Catalase↑, 2,   Ferroptosis↓, 2,   GPx↑, 2,   GPx4↑, 1,   GSH↑, 5,   GSR↑, 1,   GSSG↓, 1,   H2O2↓, 1,   lipid-P↓, 2,   MDA↓, 3,   NOX4↓, 1,   NRF2↑, 2,   Prx↑, 1,   ROS↓, 12,   ROS↑, 1,   ROS⇅, 1,   ROS∅, 1,   mt-ROS↓, 1,   RPM↝, 1,   SOD↑, 5,   TAC↑, 1,   Thiols↑, 1,   Trx↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 4,   ETC↓, 1,   MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 2,   BUN↓, 1,   GlucoseCon↓, 1,   GlucoseCon↑, 1,   Glycolysis↝, 1,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   NADPH↓, 2,   PFK2↓, 1,   PGC1A↑, 1,   PPP↓, 1,  

Cell Death(tgid=5) ⓘ

BAX↓, 1,   Bcl-2↑, 1,   Casp12↓, 1,   Casp3↓, 1,   Casp9↓, 1,   Cyt‑c↓, 1,   Ferroptosis↓, 2,   iNOS↓, 1,   iNOS↑, 1,   JNK↓, 1,   MLKL↓, 1,   RIP1↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

CaMKII ↓, 1,   Sp1/3/4↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↓, 1,   CHOP/DDIT3↓, 1,   ER Stress↓, 3,   GRP78/BiP↓, 5,   HSF1↑, 2,   HSP70/HSPA5↑, 1,   IRE1↓, 3,   PERK↓, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

mTOR↑, 1,   STAT3↓, 1,  

Migration(tgid=13) ⓘ

APP∅, 1,   E-cadherin↓, 1,   MMP2↓, 2,   Rho↓, 3,   ROCK1↓, 3,   Zeb1↓, 1,   ZO-1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   ATF4↓, 1,   eNOS↓, 1,   Hif1a↓, 1,   NO↓, 1,   VEGF↓, 1,   VEGF↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   HMGB1↓, 1,   ICAM-1↓, 1,   IL10↑, 1,   IL1β↓, 2,   IL6↓, 3,   IL8↓, 1,   Inflam↓, 9,   Inflam∅, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 4,   NF-kB↑, 1,   p‑NF-kB↓, 1,   PGE2↓, 2,   RANTES↓, 1,   TNF-α↓, 2,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 10,   BACE/β-secretase↑, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   BioAv↝, 1,   Dose↝, 6,   eff↑, 4,   Half-Life↑, 1,   Half-Life↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   ALP↓, 1,   AST↓, 2,   creat↓, 1,   GutMicro↑, 2,   IL6↓, 3,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 2,   cognitive↓, 1,   cognitive↑, 10,   hepatoP↑, 1,   memory↑, 6,   neuroP↑, 5,   OS↑, 1,   QoL↑, 1,   radioP↑, 2,   toxicity↓, 1,   toxicity∅, 2,  

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 3,  
Total Targets: 124

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page